From our news archives:
EUSA Pharma announces launch of new Caphosol website
New Caphosol Website offers comprehensive resource on Oral Mucositis and Caphosol®.
EUSA Pharma is pleased to have launched the new Caphosol website, Caphosol.com, a website developed with the goal of providing a comprehensive resource on oral mucositis to both patients and Healthcare Professionals. The site also contains the key information required to understand just what Caphosol (supersatured calcium and phosphate mouth rinse) can offer in dealing with the debilitating effects of oral mucositis.
The website is simple to use and allows fast navigation for visitors enabling them to find a wealth of information about Oral Mucositis and Caphosol along with facts and advice sheets which can be downloaded and printed. The site includes a video section that provides additional information including real patient experiences with Oral Mucositis and Caphosol. Visitors to the website are also invited to enter their own experiences with oral mucositis.
Oral mucositis (OM) is a painful side effect of cancer therapy and is typically characterised by a red, swollen and ulcerated mouth and tongue. This painful condition, associated with both chemo- and radio-therapy can prevent sufferers from talking and even from eating or drinking. In a survey of 558 nurses undertaken at the Annual Oncology Nursing Society Congress, Oral Mucositis was identified as the most debilitating problem associated with cancer therapy.1
Caphosol is a supersaturated calcium and phosphate mouth rinse which is CE marked and a Class I Medical device. Caphosol is indicated for dryness of the mouth and oropharynx (hyposalivation,
xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol is also indicated as an adjunct to standard oral care in the prevention and
treatment of the mucositis that may be caused by radiation or high dose chemotherapy. Relief of dryness of the oral mucosa in these conditions is associated with amelioration of pain. Caphosol is now available in over 40 countries around the world and for more information please visit www.caphosol.com.
About EUSA Pharma
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care products. The company has an established commercial infrastructure in the U.S., a pan-European presence and a wider distribution network in numerous additional territories. EUSA Pharma currently has a total of 10 specialist hospital products, which are sold in over 80 countries globally**. In the UK these include Erwinase®2 used in the treatment of acute lymphoblastic leukemia, Caphosol®3 for the prevention and treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, and Collatamp®4 G, a surgical implant impregnated with the antibiotic gentamicin. For further information on EUSA Pharma or the portfolio please consult
1. Bruce SD and Quinn A. US Oncological Disease 2007;1:86-90
2. Erwinase® Summary of Product Characteristics. Eusa Pharma Limited.
3. Caphosol IFU. EUSA Pharma (Europe) Limited, June 2009.
4. Collatamp® SmPc /package insert
** not all are approved for use in the USA.